Lonza Group stock trades around CHF 574 as investors weigh post-earnings reset

Lonza Group (ISIN CH0013841017) stock provides investors with a fresh price reference in mid-August 2026, with a recent quote of CHF 573.80 on the Swiss market as of August 13, 2026, following an earlier phase when the shares were recorded at CHF 450.00 on August 12, 2026 during the post-earnings reset period.

Latest trading snapshot for Lonza Group stock

Per a sector overview page dated August 13, 2026, Lonza Group AG was quoted at CHF 573.80 on the Cboe Europe book, with the market marked closed at 5:20 p.m. local time for that session. The same overview shows a 5-day performance of plus 1.34 percent and a year-to-date gain of 1.36 percent, giving investors context for the recent move.

A prior article focusing on Lonza stock documented a reference level of CHF 450.00 as of August 12, 2026, with a market capitalization of CHF 38.0 billion at the time. That earlier snapshot was taken on the SIX Swiss Exchange close at 4:00 p.m. CET, positioning CHF 450.00 as a baseline against which the newer CHF 573.80 quote can be compared.

This comparison shows that between the CHF 450.00 level on August 12, 2026 and the CHF 573.80 quote captured on August 13, 2026, the market reference for Lonza Group has shifted materially higher, indicating an increase of CHF 123.80 per share or 27.51 percent in nominal terms across the two disclosed data points.

Fundamental context and earnings reset

The earlier market snapshot at CHF 450.00 was explicitly tied to a narrative of an earnings reset following the company’s 2024 results, reflecting how investors were recalibrating valuation and expectations on the back of that reporting period. While the article referencing CHF 450.00 does not list concrete revenue or profit numbers, it clearly positions 2024 as the fiscal year around which the reset discussion revolves.

Because the 2024 fiscal year would have ended within 24 months of August 14, 2026, those results can still be considered part of the current fundamental backdrop, even if the article itself focuses more on valuation and execution than on detailed income statement metrics. In that context, the CHF 38.0 billion market capitalization cited for August 12, 2026 serves as a key valuation marker.

With the more recent CHF 573.80 quote now visible on August 13, 2026, investors can infer that the market value has expanded compared with the CHF 38.0 billion level at CHF 450.00, assuming the share count has remained broadly stable. The magnitude of the nominal share price increase points to a meaningful re-rating in the space of one trading day in the recorded snapshots.

Analyst and consensus view from sector overview

The same sector consensus page that lists the CHF 573.80 price and the short-term performance metrics also provides a framework for understanding how market participants are viewing the stock in relation to peers. By compiling sector-wide data and recent price performance, it offers investors a way to contextualize Lonza Group’s moves against other companies in the broader healthcare and contract manufacturing field.

Seeing a 1.34 percent rise over five days and a 1.36 percent year-to-date gain suggests that, at least based on this single overview, Lonza stock has been relatively steady rather than extremely volatile, even though the jump from CHF 450.00 to CHF 573.80 between the two referenced dates hints at individual sessions with more pronounced movement.

For investors tracking contract development and manufacturing organizations, Lonza’s valuation story in mid-2026 continues to depend on execution in biologics manufacturing, small molecule services, and cell and gene therapy capabilities, as well as on how management’s guidance evolves after the 2024 results period that initially triggered the reset narrative.

Representative product and business footprint

One representative area of Lonza Group’s business is its biologics contract manufacturing segment, which produces monoclonal antibodies and other complex biologic therapies for pharmaceutical and biotechnology clients. In this segment, Lonza designs and operates large-scale manufacturing facilities and offers services that span process development, scale-up, and commercial production, supporting customers that need reliable capacity for clinical and commercial launches.

These manufacturing services are typically delivered under long-term contracts, creating a revenue stream that depends on capacity utilization, quality performance, and regulatory compliance. For investors, the relevance of this segment lies in its potential to deliver recurring revenue and margins if facilities remain well utilized and customers continue to expand their pipelines.

Closing view on Lonza Group stock

As of August 13, 2026, the latest displayed quote of CHF 573.80 on the Cboe Europe market provides a current reference level for Lonza Group stock, complementing the CHF 450.00 snapshot from August 12, 2026 on the SIX Swiss Exchange and highlighting a pronounced short-term change in the recorded price landscape.

Fact box

Company: Lonza Group AG

ISIN: CH0013841017

Ticker: LONN

Exchange: SIX Swiss Exchange

Price (as of August 13, 2026, market close): CHF 573.80

Market cap: CHF 38.0 billion (as of August 12, 2026, at CHF 450.00)

Sector / Industry: Healthcare - Contract manufacturing and services

Index membership: Swiss Market Index